Moderate Psoriasis Epidemiology Forecast 2025-2034

Moderate psoriasis is a skin condition characterized by red, scaly patches covering approximately 3% to 10% of the body. Typically, arms, legs, scalp, and torso are affected by the patches. Moderate psoriasis epidemiology forecast indicates that 80% of psoriasis patients have mild to moderate forms of this autoimmune disease. A 2021 clinico-epidemiological study on 40 patients with moderate to severe plaque psoriasis found that 62.5% had moderate psoriasis, with an average disease duration of 8.93 years. Moderate psoriasis was associated with significant comorbidities (72%), particularly dyslipidemia and a reduced quality of life.

Moderate Psoriasis Epidemiology Forecast Report Coverage

The “Moderate Psoriasis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of moderate psoriasis. It projects the future incidence and prevalence rates of moderate psoriasis cases across various populations. The study covers age and type as major determinants of the moderate psoriasis population. The report highlights patterns in the prevalence of moderate psoriasis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on moderate psoriasis epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Moderate Psoriasis Understanding: Disease Overview

Psoriasis is a chronic autoimmune skin disorder that causes scaling, inflammation, and redness. Moderate psoriasis usually presents as well-defined, raised, red patches, with many patients experiencing itching, burning, and discomfort. A combination of environmental and genetic factors can contribute to the development of moderate psoriasis. Stress, infections, skin injuries, lifestyle factors (alcohol use and smoking), and certain medications can also trigger the condition. Moderate psoriasis is often associated with comorbid conditions, including metabolic syndrome, cardiovascular disease, psoriatic arthritis, and depression.

Moderate Psoriasis Epidemiology Perspective

The moderate psoriasis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for moderate psoriasis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. the moderate psoriasis detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Various studies suggest that about 80% of psoriasis patients are affected by localized, mild-to-moderate forms of the condition, often involving plaques on the scalp, elbows, trunk, and/or knees.
• When 3% to 10% of the body, including regions such as arms, scalp, and legs, has patches, the skin condition is considered moderate psoriasis.
• The global prevalence of psoriasis is estimated to be around 8.5% in adults and 2.1% in children, with the skin manifestations generally not fatal for the patient.
• As per an article published in Dermatology and Therapy (2021), 78% of people with psoriasis have mild or moderate disease with less than 10% of body surface area affected.
• The average age of psoriasis onset is 33 years, but it tends to appear earlier in women than in men. In women, it commonly develops between 16 to 2 years or 55 to 60 years, while in men, the onset typically occurs between 30 to 39 years or 60 to 79 years, as per a systematic analysis and modelling study (2020).

Country-wise Moderate Psoriasis Epidemiology Segment

The moderate psoriasis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of moderate psoriasis varies significantly between countries due to differences in genetic predispositions, environmental factors, access to healthcare (including dermatological services and treatments), diagnostic criteria, and public health awareness, among others. In the United States, more than 8 million people are affected by psoriasis, including moderate psoriasis, as per the National Psoriasis Foundation.

Moderate Psoriasis: Treatment Overview

For the treatment of moderate psoriasis, a combination of phototherapy, topical therapies, and systemic medications is used. When the affected areas are localized, topical therapies are prescribed as a first-line treatment for managing inflammation, itching, and scaling. Vitamin D analogues like calcipotriol and calcitriol help in slowing down keratinocyte overproduction and clearing plaques.

Phototherapy or light therapy is commonly recommended for moderate psoriasis patients who don't respond adequately to topical treatments. Narrowband UVB (NB-UVB) and Psoralen and UVA (PUVA) are the widely used light therapies. Advances in treatment options are rapidly changing the moderate psoriasis market, with more than 13 FDA-approved biologics available for moderate to severe psoriasis. Moreover, there have been new regulatory approvals for topical and oral therapies for better psoriasis management.

Key Questions Answered

• What are the key findings of moderate psoriasis epidemiology in the 8 major markets?
• What will be the total number of patients with moderate psoriasis across the 8 major markets during the forecast period?
• What was the country-wise moderate psoriasis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of moderate psoriasis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of moderate psoriasis during the forecast period of 2025-2034?
• What are the currently available treatments in the moderate psoriasis market?
• What are the disease risks, signs, symptoms, and unmet needs of moderate psoriasis?

Scope of the Moderate Psoriasis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of moderate psoriasis based on several factors.
• The Moderate Psoriasis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The moderate psoriasis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.